Checkpoint Therapeutics, Inc. - Common Stock (CKPT)
3.9800
-0.0200 (-0.50%)
Checkpoint Therapeutics Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative treatments for cancer
The company specializes in targeted and immune-oncology therapies, aiming to advance new options for patients suffering from various types of solid tumors. Through its research initiatives and clinical trials, Checkpoint Therapeutics seeks to develop therapies that can effectively address unmet medical needs in oncology, leveraging modern scientific advancements to enhance patient outcomes.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top gainers and losers in today's session.
The session on Monday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Sun Pharma to acquire Checkpoint Therapeutics for $4.10 per share, with potential CVR. FDA approves Unloxcyt, the first PD-L1 blocker for advanced cSCC.
Checkpoint Therapeutics' Unloxcyt wins FDA approval for advanced cSCC, marking the company's entry into the U.S. market, valued over $1 billion annually.
CKPT stock results show that Checkpoint Therapeutics missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
Shares of Compugen Ltd. (NASDAQCGEN) shares rose sharply during Tuesday’s session after Gilead announced an agreement with the company to exclusively license its novel pre-clinical immunotherapy program. Compugen shares jumped 204.1% to $2.22 on Tuesday.
U.S. stocks traded mostly higher toward the end of trading, with the Nasdaq Composite gaining over 100 points on Monday. The Dow traded up 0.01% to 37,307.40 while the NASDAQ rose 0.71% to 14,919.07. The S&P 500 also rose, gaining, 0.54% to 4,744.58.
Shares of Lantheus Holdings, Inc. (NASDAQLNTH) fell sharply during Monday’s session after the company and POINT Biopharma announced topline results from the pivotal phase 3 SPLASH study in metastatic castration-resistant prostate cancer.
